Você procurou por: remodelling (Inglês - Maltês)

new bone formation and bone remodelling
formazzjoni ta’ għadam ġdid u mmudellar mill-ġdid tal-għadam

this process is called remodelling.
dan il-proċess jissejjaħ rimudellar.

sugammadex has no effects on fracture repair and remodelling of bone.
sugammadex ma għandu ebda effett fuq it-tiswija tal-ksur u l-immudellar mill-ġdid tal-għadam.

optruma and oestrogen affect bone remodelling and calcium metabolism similarly.
optruma u l-estroġenu jeffetwaw bl-istess mod ir-rimodellar ta’ l-għadam u l-metaboliżmu tal-calcium.

all glucocorticoids increase calcium excretion and reduce the bone-remodelling rate.
il-glukokortikojdi kollha jżidu l-eskrezzjoni tal-kalċju u jnaqqsu r-rata ta’ rimudellar tal-għadam.

bone biopsy results showed bone of normal quality with no evidence of impaired bone remodelling and no evidence of mineralisation defects.
riżultati ta’ bijopsiji tal-għadam urew għadam ta’ kwalità normali mingħajr ebda ħjiel ta’ indeboliment fir-rimudellar tal-għadam u ebda ħjiel ta’ difetti tal-mineralizzazzjoni.

aclasta works by returning the bone remodelling process to normal, securing formation of normal bone, thus restoring strength to the bone.
aclasta jaħdem billi jreġġa’ lura għan-normal il-proċess ta’ rimudellar tal-għadam, jiżgura l-formazzjoni ta’ għadam normali, b’hekk jagħti lura s-saħħa lill- għadam.

this is in addition to the nancial support for the purchase of the shop space, including its remodelling and equipment, and promotional and marketing materials.
dan minbarra lappoġġ -nanzjarju għax-xiri ta’ l-ispazju tal-ħanut inkluż l-immudel-lar mill-ġdid u t-tgħammir tiegħu; u l-materjali promozzjonali u ta’tqegħid s-suq.

although the precise mechanism of action is not yet clearly defined, aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction.
għalkemm il-mekkaniżmu ta’ azzjoni preċiż s’issa mhuwiex mfisser b’mod ċar, aldosterone jippromwovi l-fibrożi mijokardijali, mudellar mijokardijali u vaskulari mill-ġdid u l-funzjoni ħażina ta’ l-endotilju.

in experimental models in dogs, it was shown that long term therapy with an aldosterone antagonist prevents progressive left ventricle dysfunction and attenuates left ventricle remodelling in dogs with chronic heart failure.
f’mudelli sperimentali fil-klieb, kien muri li terapija fuq tul ta’ żmien ma’ antagonist ta’ aldosterone jimpedixxi l-funzjoni ħażina progressiva tal-ventrikolu tax-xellug u jimmodera l-immudellar mill-ġdid tal-ventrikolu tax-xellug fi klieb b’falliment kroniku tal-qalb.

in a 36-week study involving 820 patients with ischaemic left ventricular dysfunction, no changes in ventricular remodelling as assessed by left ventricular end systolic volume were detected with aliskiren compared to placebo on top of background therapy.
waqt studju li dam għaddej 36 ġimgħa fost 820 pazjent b’disfunzjoni iskemika tal-ventrikolu xellugi, ma deher l-ebda tibdil fl-immudellar mill-ġdid tal-ventrikolu li kien evalwat permezz tal- volum sistoliku aħħari tal-ventrikolu xellugi b’aliskiren meta mqabbel mal-plaċebo fil-quċċata tat- terapija ta’ sfond.

serum levels of matrix metalloproteinases (mmp-1 and mmp-3) that produce tissue remodelling responsible for cartilage destruction were also decreased after humira administration.
il-livelli fis- serum ta’ metalloproteinases fil-matriċi (mmp-1 u mmp-3) li jipproduċu tibdil fit-tessuti li hu responsabbli għall-qerda tal-qarquċa, naqsu ukoll wara li ngħata humira.

predominant actions of et-1 binding to eta are vasoconstriction and vascular remodelling, while binding to etb results in et-1 clearance, and vasodilatory/ antiproliferative effects due in part to nitric oxide and prostacyclin release.
l-effetti predominanti tat-twaħħil ta’ et-1 ma’ eta huma, vasorestrizzjoni u mmudellar vaskulari mill-ġdid, filwaqt li t-twaħħil ma’ etb jirriżulta fl-eliminazzjoni ta’ et-1, u f’effetti vasodilatorji/antiproliferattivi li parti minnhom huma effetti tal-liberazzjoni ta’ nitric oxide u prostacyclin.